Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib-Reference-Cited by-同舟云学术

Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib

Published:2021-12 Issue:6 Volume:45 Page:100734
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Kummar Shivaani,Berlin Jordan,Mascarenhas Leo,van Tilburg Cornelis M.,Geoerger Birgit,Lassen Ulrik N.,Schilder Russell J.,Turpin Brian,Nanda Shivani,Keating Karen,Childs Barrett H.,Chirila Costel,Laetsch Theodore W.,Hyman David M.,Drilon Alexander,Hong David S.

Funder

Bayer HealthCare Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology;McKee;Oncologist,2010

2. The cancer patient and quality of life;Bottomley;Oncologist,2002

3. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007;Sridhara;J Natl Cancer Inst.,2010

4. World Health Organization. Cancer diagnosis and treatment, 2019. Available at: https://www.who.int/cancer/treatment/en/ Accessed July 30, 2019.

5. Early palliative care in cancer treatment: rationale, evidence and clinical implications;Howie;Ther Adv Med Oncol.,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland;Acta Oncologica;2024-07-05

2. Safety of current treatment options for NTRK fusion-positive cancers;Expert Opinion on Drug Safety;2023-10-31

3. The efficacy of the TRK inhibitor entrectinib in patients with extracranial <i>NTRK</i> fusion-positive tumors;Pediatric Hematology/Oncology and Immunopathology;2023-09-30

4. TrkA Co-Receptors: The Janus Face of TrkA?;Cancers;2023-03-23

5. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib;BMC Cancer;2022-06-07